Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12393940 | 0.96 | LMNA (0.52) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL14996276 | 0.88 | LMNA (0.54) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL27647417 | 0.88 | SMN1; SMN2 (0.56) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL21620361 | 0.84 | LMNA (0.56) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL7657748 | 0.84 | LMNA (0.59) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL4139120 | 0.84 | HTT (0.54) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL4139126 | 0.84 | HTT (0.54) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| Hydrochloric Acid SCHEMBL21616407 | 0.83 | LMNA (0.55) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL867055 | 0.82 | LMNA (0.61) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL4140555 | 0.82 | LMNA (0.54) | SMN1; SMN2LMNAHTTL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3238738-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | Arbutus Biopharma Corporation (CA) | 2017-11-01 | — | — | EP | disclosed |
| EP-2355658-B1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORP (CA) | 2017-09-27 | — | — | EP | disclosed |
| US-9764036-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-09-19 | — | — | US | disclosed |
| US-20160213785-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2016-07-28 | — | — | US | disclosed |
| US-20160074381-A1 | MODULATORS OF CELLULAR ADHESION | SARCODE BIOSCIENCE INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-9248126-B2 | Modulators of cellular adhesion | SARCODE BIOSCIENCE INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9220683-B2 | Lipids and compositions for the delivery of therapeutics | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2015-12-29 | — | — | US | disclosed |
| US-9216174-B2 | Modulators of cellular adhesion | SARCODE BIOSCIENCE INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-8987504-B2 | Aminohydroxylation of alkenes | VICTORIA LINK LIMITED (NZ) | 2015-03-24 | — | — | US | disclosed |
| US-20140200257-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-07-17 | — | — | US | disclosed |
| US-8748626-B2 | Oxazole and thiazole compounds as KSP inhibitors | NOVARTIS AG (CH) | 2014-06-10 | — | — | US | disclosed |
| US-20140066476-A1 | MODULATORS OF CELLULAR ADHESION | SARCODE BIOSCIENCE INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140056880-A1 | TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2014-02-27 | — | — | US | disclosed |
| US-20140051675-A1 | MODULATORS OF CELLULAR ADHESION | SARCODE BIOSCIENCE INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8546434-B2 | Triazole compounds as KSP inhibitors | NOVARTIS AG (CH) | 2013-10-01 | — | — | US | disclosed |
| US-20130224186-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2013-08-29 | — | — | US | disclosed |
| US-20120095075-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120027796-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2010054406-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160213785-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | SMN1; SMN2 1515/4885LMNA 974/4885HTT 1231/4885 |
| US-20140066476-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | SMN1; SMN2 2217/4885LMNA 1395/4885HTT 4288/4885 |
| US-20140200257-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | LIPG, EGFR, LDLR | SMN1; SMN2 3403/4885LMNA 1590/4885HTT 2096/4885 |
| US-20130224186-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS KSP INHIBITORS | SLCO2B1, OXA1L, SLCO2A1 | SMN1; SMN2 3242/4885LMNA 4429/4885HTT 3760/4885 |
| US-20140051675-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | SMN1; SMN2 2217/4885LMNA 1395/4885HTT 4288/4885 |
| US-20160074381-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | SMN1; SMN2 2217/4885LMNA 1395/4885HTT 4288/4885 |
| US-20120095075-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | SMN1; SMN2 1568/4885LMNA 975/4885HTT 1260/4885 |
| US-20140056880-A1 | TRIAZOLE COMPOUNDS AS KSP INHIBITORS | CYP17A1, CYP51A1, KLKB1 | SMN1; SMN2 2900/4885LMNA 3742/4885HTT 3176/4885 |
| US-20120027796-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, ABCB4, LCAT | SMN1; SMN2 1022/4885LMNA 773/4885HTT 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.